Breaking News

GW Pharmaceuticals gains product recognition by NHS England

GW Pharmaceuticals gains product recognition by NHS England

Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) have been recommended for use by the UK’s National Institute for Health and Care Exc...
AC Immune and Lilly announce licence and collaboration agreement

AC Immune and Lilly announce licence and collaboration agreement

Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerativ...
Axol Bioscience launches human iPSC-derived microglia

Axol Bioscience launches human iPSC-derived microglia

A reproducible, physiologically relevant cellular model of human microglia for neurodegenerative disease drug discovery and development
Nano CBD: Cannabidiol made with the human body in mind

Nano CBD: Cannabidiol made with the human body in mind

Infinite CBD's Ali Munk explains how CBD products work, and why choosing nanotechnology as drug delivery increases its bioavailability
New approaches to treat psychiatric disorders

New approaches to treat psychiatric disorders

Cardiff University forms new drug discovery collaboration for psychiatric disorders
Personalised medication is becoming an increasing possibility for patients

Personalised medication is becoming an increasing possibility for patients

A long sought after objective of healthcare is to ensure that each patient receives tailored treatment for their medical situation
Alzheimer’s disease: a new therapeutic strategy

Alzheimer’s disease: a new therapeutic strategy

Probiodrug’s novel approach to Alzheimer’s targets a modified form of ß-amyloid, which has a key role in the formation of toxic Aß oligomers. The c...
Antiepileptic drugs increase risk of Alzheimer’s and dementia

Antiepileptic drugs increase risk of Alzheimer’s and dementia

The use of antiepileptic drugs is associated with an increased risk of Alzheimer’s disease and dementia, according to a new study from the Universi...
In search of a biomarker

In search of a biomarker

Altered bacterial communities in the gut could be an indicator for Parkinson’s disease
Invent Farma/neuraxpharm Group announces the acquisition of FB Health in Italy

Invent Farma/neuraxpharm Group announces the acquisition of FB Health in Italy

The Invent Farma/neuraxpharm Group, a leading specialty generics company focussed on CNS, has announced the acquisition of FB Health, an Italy base...
Leading charity calls for government to confirm plans for dementia research

Leading charity calls for government to confirm plans for dementia research

Alzheimer's Research UK’s call comes amid speculation that the Great Repeal Bill – aimed at ensuring EU law will no longer apply in the UK after Br...

In Brief

Antidepressant use increases risk of head injuries among persons with Alzheimer’s disease

Cypralis Limited announces grant award

Researchers find a potential target for anti-Alzheimer treatments

Alkermes to initiate second Phase III study of ALKS 3831 for schizophrenia

Alkermes submits NDA to FDA for aripiprazole lauroxil for treatment of schizophrenia

Alkermes initiates FORWARD-5 clinical study of ALKS 5461

Alkermes to present data on new medicines in development for schizophrenia and depression

Reports

Nano CBD: Cannabidiol made with the human body in mind
Nano CBD: Cannabidiol made with the human body in mind
Alzheimer’s disease: a new therapeutic strategy
Alzheimer’s disease: a new therapeutic strategy